LIVE POLIO IRUS VACCINES

Index
627
Reversion
dangers of, 485
due to mutation in culture media, 505
eliminated by coverage of population, 420, 584
objection to use of live vaccine, 414
to produce paralytic disease, 458, 497
Rhesus monkeys (Macaca mulatta)
detection of inapparent virus infection, 85
in IM vaccine tests, technique, 90
IS and IC inoculation, 68
Rhim, J., paper 377-385
Rhodes, Andrew J., 457, 460, 464-465, 480, 481
Ribonucleic acid
and d marker study, 44
classic patterns in DNA genetics not applicable,
190
infectivity from "hot" and "cold" virus, 63
MS cell, infection rate, 61
mutation by changing composition, 5, 110
not produced by "cold" variant at high temperatures,
63
size equivalent of one gene, 47
Richardson, Suzanne, 473
Riordan, John T., paper 174-184; 139
Ritts, Raymond D., 4
Rivas, Nicaragua
epidemic, 1959-60, 547
RNA, see Ribonucleic acid
Robbins, Frederick C., paper 302-307; 45, 49, 324-
325, 327
Roca-García, M., paper 31-37, 330-340
Rocky Mountain spotted fever vaccine
subjects sensitized by insufficient antigen, 374
Rodrigues island
field trial, 477-478
RSFSR
three vaccinations 1960, 419, 582
RSSE antibodies
sera examined for, 535
Rubin, H., 8
Ruegsegger, James M., paper 330-340; 437
Russia, see Soviet Union
Rustin, George, 97, 131
RVA, see Residual virus activity
SA viruses
see Simian virus
Sabin, Albert B., paper 101-108, 315-322, 377-385; 5-6,
18, 23, 28-29, 34-35, 39, 42, 45, 49, 66, 87, 90,
100, 109, 122, 124, 132-133, 143, 145, 157, 159.
192-193, 199, 205, 228, 236, 275, 308-309, 324,
329, 371, 373, 376, 410-411, 430, 432, 482,
505, 576-577, 579-580, 591, 593-598
Sabin strains, see Vaccine, Attenuated
Safety
and change in markers, 7
and epidemiological considerations, 29
based on susceptibles, 12
Czechoslovakia, 507
evaluation, 6, 47
for contacts, 454
Leopoldville, Congo, 466-473
Minnesota, 462
Safety-continued
need for, 576
no reversion, 577
no untoward reactions, 400
question has been settled, 463
Sabin's attenuated strains, 120, 482, 576
Soviet Union, 494, 584
tests need simplification and improvement, 584
vaccinees and community, 141
virulence greatly increased after 180th passage, 474
St. Cloud Reformatory, Minnesota, 357
St. Joseph's Abbey
closed-institution study, 332-333
St. Paul, Minnesota
mass trial, 17,000 participants, 461
St. Petersburg, Florida
infectious central nervous system disease epidemic.
458-459
Saline
induced trauma by injecting IC, 98
Salk vaccine, see Vaccine, Killed (Salk)
Salk and Youngner pH test, see pH test
Salt, see Sodium chloride
San José, Costa Rica, 113
house-to-house campaign, 561
investigation of polio reports, 569
ten cases in vaccinees, 571
vaccination program, 1960, 563
Sanderson, I. T., 79
Sanitary facilities
Toluca and Cincinnati, compared, 591
Santo Domingo de Heredia, Costa Rica
field trial, 113-120
Schaeffer, Morris, 34
Schar, M., 124, 322-323
Schneider, N. J., paper 435-444; 439
Sciatic nerve
surgical section, to determine route to CNS, 94
Seasons
and polio incidence, 386, 437, 493, 494, 453
conditions for successful immunization, 578
decline occurred independent of vaccination, 411
Sottunga trial, 535
Seattle
high attack rate in unvaccinated, 575
Seitz pad, 124
Selective advantage
mutants in first passage tissue culture, 109
Sensitizing agent
vaccine with low antigen, 374
Serial transfer
from one child to another, 7
Seroimmunity
acquired during first 4 years, 386
related to spread and poliomorbidity, 520
Serologic immunity
in population group, 542
Serologic survey
liquid and candy vaccine, 416
monovalent and trivalent, 240, 365, 366, 384
sampling adequacy, 559
Serological response
and virological findings correlated, 272